CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

You are here

Products

back to search results

INI1/SNF5/BAF47 [25]

Product group: Primary
Monoclonal/ Polyclonal: Monoclonal
Clone: 25
Host: Mouse
Isotype: IgG2a
Application: Immunohistochemistry (IHC), Western Blot (WB)
Application notes: 25-100
Conjugation Type: Unconjugated
Reactivity: Human
General notes: Localization: nucleus.
Buffer: Citrate pH6.0 or EDTA pH8.0
UNSPSC code: 12352203

The INI-1 gene, which encodes a functionally uncharacterized protein component of the hSWI/SNF chromatin remodeling complex, is often mutated or deleted in malignant rhabdoid tumor (MRT). Two isoforms of INI-1, that differ by the variable inclusion of amino acids, potentially are produced by differential RNA splicing. The morphology of MRTs can present challenges in differential diagnosis. The overall survival of MRTs relative to its potential mimics (medulloblastoma, supratenorial primitive neuroectodermal tumors (sPNETs)) is quite low, and thus differentiation from these other tumors is desirable. Lack of nuclear labeling by anti-INI-1 is characteristic of MRT. The majority of medulloblastomas and sPNETs are labeled by anti-INI-1. MRTs also originate from the kidney and soft tissues. (Shipping Cost: €200.00)

INI1/SNF5/BAF47 [25]

The INI-1 gene, which encodes a functionally uncharacterized protein component of the hSWI/SNF chromatin remodeling complex, is often mutated or deleted in malignant rhabdoid tumor (MRT). Two isoforms of INI-1, that differ by the variable inclusion of amino acids, potentially are produced by differential RNA splicing. The morphology of MRTs can present challenges in differential diagnosis. The overall survival of MRTs relative to its potential mimics (medulloblastoma, supratenorial primitive neuroectodermal tumors (sPNETs)) is quite low, and thus differentiation from these other tumors is desirable. Lack of nuclear labeling by anti-INI-1 is characteristic of MRT. The majority of medulloblastomas and sPNETs are labeled by anti-INI-1. MRTs also originate from the kidney and soft tissues.